|Articles|May 1, 2001

May 2001
Volume 7
Issue 5

Total Cost Comparison of 2 Biopsy Methods for Nonpalpable Breast Lesions

Author(s)Balazs I. Bodai, MD, Beth Boyd, RN, Lurlene Brown, MD

Download PDF: Total Cost Comparison of 2 Biopsy Methods for Nonpalpable Breast Lesions

Articles in this issue

over 25 years ago

Article

Patient's Knowledge of Health Plan Coverage and Satisfaction with Care

over 25 years ago

Article

Development and Validation of the Pharmaceutical Care Satisfaction Questionnaire

over 25 years ago

Article

Health Insurance, Primary Care, and Preventable Hospitalization of Children in a Large State

over 25 years ago

Article

Impact of HMO Ownership on Management Processes and Utilization Outcomes

over 25 years ago

Article

Diabetes Mellitus in Managed Care: Complications and Resource Utilization

over 25 years ago

Article

Impact of Managed MediCal on California Family Practice Programs

over 25 years ago

Article

Treatment of Hypertension in a Managed Care Setting

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Total Cost Comparison of 2 Biopsy Methods for Nonpalpable Breast Lesions

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies